Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + Chemoradiotherapy for HER2+ GEJ Adenocarcinoma
NCT03368131Phase 2Unknown
- Sponsor
- Hebei Medical University
- Start
- Dec 2017
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in gastroesophageal junction adenocarcinoma, sponsored by Hebei Medical University. Status: unknown.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03368131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03368131.